International data available on booster doses of AstraZeneca and Covishield suggests a three-to four-fold increase in antibody levels after their administration, Bharati Pravin Pawar, Minister of State for Health, said in a written reply in Rajya Sabha yesterday
A study by the Indian Council of Medical Research (ICMR) to examine the effect of Covaxin’s booster dose has shown an increase in the levels of antibodies against SARS-CoV-2, Bharati Pravin Pawar, Minister of State for Health, told the Rajya Sabha yesterday.
International data available on booster doses of AstraZeneca and Covishield suggests a three-to four-fold increase in antibody levels after their administration, Pawar said in a written reply.
A study has been conducted by ICMR to examine the effect of booster dose of Covaxin which shows increase in the levels of neutraliing antibodies against SARS-CoV-2 after the booster dose,” Pawar stated.
As per the recommendation of the National Technical Advisory Group on Immunisation (NTAGI), precaution dose is administered to healthcare workers, frontline workers, and people aged 60 years and above since 10th January, 2022, she said.